Patents by Inventor Stephen W. Hadley

Stephen W. Hadley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5217705
    Abstract: A fibrin-binding protein such as t-PA is labeled with a detectable substance, such as a radionuclide, and administered to a patient for diagnosis of blood clots and for monitoring the dissolution thereof during therapy. The detectable substance preferably is attached to t-PA through linkers which specifically bind to the portion of the t-PA protein responsible for enzymatic activity, thereby diminishing this activity while leaving the fibrin-binding property of the protein intact.
    Type: Grant
    Filed: September 22, 1988
    Date of Patent: June 8, 1993
    Assignee: Neorx Corporation
    Inventors: John M. Reno, Stephen W. Hadley, Marjorie A. Mohler
  • Patent number: 5200169
    Abstract: Vinyl radiohalogenated small molecules as shown in formulas I and II: ##STR1## wherein *X is radiohalogen, C.dbd.C is a double bonded set of sp.sup.2 hybridized carbon atoms, and substituents R.sub.1, and R.sub.2 are as defined in the specification. Y is a substituent containing any of the groups described for R.sub.1 and R.sub.2, except that Y cannot be hydrogen, and bearing a functional group suitable for binding to protein under conditions that preserve the biological activity of the protein. The compounds of formulas I and II can be coupled to proteins such as monoclonal antibodies to provide reagents for diagnostic and therapeutic applications. Also metalated precursors of compounds I and II, as well as radiopharmaceutical reagent kits containing any of the subject small molecules.
    Type: Grant
    Filed: July 5, 1989
    Date of Patent: April 6, 1993
    Assignee: NeoRx Corporation
    Inventors: Daniel S. Wilbur, Stephen W. Hadley
  • Patent number: 5102651
    Abstract: A process for recovering At-211 from a target and simultaneously producing an At-211-labeled radiopharmaceutical agent involves introducing volatilized At-211, produced by dry distillation of an irradiated Bi-209 target, into a solution containing a compound that binds the At-211 to form an At-211-labeled radiopharmaceutical agent. The radiopharmaceutical agent may have therapeutic use as is, or may be attached to a targeting protein such as an antibody prior to administation to a patient.
    Type: Grant
    Filed: December 29, 1989
    Date of Patent: April 7, 1992
    Assignee: NeoRx Corporation
    Inventors: Daniel S. Wilbur, Stephen W. Hadley
  • Patent number: 4870188
    Abstract: Vinyl radiohalogenated small molecules as shown in formulas I and II: ##STR1## wherein *X is a radiohalogen, C.dbd.C is a double bonded set of sp.sup.2 hybridized carbon atoms, and substituents R.sub.1, R.sub.2, and Y are as defined below. R.sub.1 and R.sub.2 are substituents independently selected from among hydrogen; alkyl or substituted alkyl, provided that any sp.sup.2 or sp carbon atom substituted on the alkyl is separated from C.dbd.C by at least one fully substituted sp.sup.3 carbon atom; aryl or substituted aryl, provided that the aryl is bonded directly to C.dbd.C; heteroalkyl, provided, first, that no heteroatom of the heteroalkyl bonds directly to C.dbd.C and, second, that any sp.sup.2 or sp hybridized carbon bonded to a heteroatom of the heteroalkyl is not bonded directly to or otherwise conjugated with C.dbd.C and, third, that where a single sp.sup.3 carbon intervenes between C.dbd.C and an sp.sup.2 or sp carbon bonded to a heteroatom that intervening sp.sup.
    Type: Grant
    Filed: April 16, 1987
    Date of Patent: September 26, 1989
    Assignee: NeoRx Corporation
    Inventors: Daniel S. Wilbur, Stephen W. Hadley